AIkido Pharma (AIKI) Competitors $1.23 +0.14 (+12.84%) As of 01/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends AIKI vs. BIAF, DKDCA, ISPC, IQV, ICLR, INCY, MEDP, CRL, MXCT, and OABIShould you be buying AIkido Pharma stock or one of its competitors? The main competitors of AIkido Pharma include bioAffinity Technologies (BIAF), Data Knights Acquisition (DKDCA), iSpecimen (ISPC), IQVIA (IQV), ICON Public (ICLR), Incyte (INCY), Medpace (MEDP), Charles River Laboratories International (CRL), MaxCyte (MXCT), and OmniAb (OABI). These companies are all part of the "commercial physical research" industry. AIkido Pharma vs. bioAffinity Technologies Data Knights Acquisition iSpecimen IQVIA ICON Public Incyte Medpace Charles River Laboratories International MaxCyte OmniAb AIkido Pharma (NASDAQ:AIKI) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, community ranking, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings. Do analysts recommend AIKI or BIAF? bioAffinity Technologies has a consensus price target of $6.00, indicating a potential upside of 788.89%. Given bioAffinity Technologies' stronger consensus rating and higher probable upside, analysts plainly believe bioAffinity Technologies is more favorable than AIkido Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AIkido Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00bioAffinity Technologies 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings and valuation, AIKI or BIAF? AIkido Pharma has higher earnings, but lower revenue than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAIkido Pharma$10K674.66-$7.17M-$3.88-0.32bioAffinity Technologies$2.53M4.16-$7.94M-$0.82-0.82 Is AIKI or BIAF more profitable? AIkido Pharma has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -91.22%. AIkido Pharma's return on equity of -18.21% beat bioAffinity Technologies' return on equity.Company Net Margins Return on Equity Return on Assets AIkido PharmaN/A -18.21% -16.94% bioAffinity Technologies -91.22%-205.09%-115.95% Do institutionals & insiders believe in AIKI or BIAF? 10.9% of AIkido Pharma shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 8.6% of AIkido Pharma shares are owned by insiders. Comparatively, 35.1% of bioAffinity Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community prefer AIKI or BIAF? AIkido Pharma received 100 more outperform votes than bioAffinity Technologies when rated by MarketBeat users. However, 100.00% of users gave bioAffinity Technologies an outperform vote while only 63.92% of users gave AIkido Pharma an outperform vote. CompanyUnderperformOutperformAIkido PharmaOutperform Votes10163.92% Underperform Votes5736.08% bioAffinity TechnologiesOutperform Votes1100.00% Underperform VotesNo Votes Does the media refer more to AIKI or BIAF? In the previous week, bioAffinity Technologies had 1 more articles in the media than AIkido Pharma. MarketBeat recorded 1 mentions for bioAffinity Technologies and 0 mentions for AIkido Pharma. AIkido Pharma's average media sentiment score of 0.00 equaled bioAffinity Technologies'average media sentiment score. Company Overall Sentiment AIkido Pharma Neutral bioAffinity Technologies Neutral Which has more volatility & risk, AIKI or BIAF? AIkido Pharma has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, bioAffinity Technologies has a beta of 2.98, indicating that its share price is 198% more volatile than the S&P 500. SummarybioAffinity Technologies beats AIkido Pharma on 9 of the 17 factors compared between the two stocks. Get AIkido Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AIKI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIKI vs. The Competition Export to ExcelMetricAIkido PharmaCommercial physical research IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.75M$4.27B$5.38B$9.13BDividend YieldN/A1.77%5.37%4.00%P/E Ratio-0.3253.5186.9417.29Price / Sales674.6645.341,267.38137.12Price / CashN/A27.3736.6032.88Price / Book0.063.434.974.69Net Income-$7.17M$139.50M$117.89M$224.57M7 Day Performance19.42%5.54%1.72%1.69%1 Month Performance-2.38%-2.00%3.67%5.34%1 Year Performance-44.84%20.65%26.11%21.47% AIkido Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIKIAIkido PharmaN/A$1.23+12.8%N/A-44.8%$6.75M$10,000.00-0.324BIAFbioAffinity Technologies2.4936 of 5 stars$0.68-6.8%$6.00+788.9%-56.2%$10.52M$2.53M-0.8210Gap UpDKDCAData Knights AcquisitionN/A$1.16+6.4%N/A+169.8%$6.00MN/A-6.102High Trading VolumeISPCiSpecimen1.0083 of 5 stars$2.37-16.8%N/A+406.6%$2.28M$9.93M-0.1260News CoverageGap UpHigh Trading VolumeIQVIQVIA4.7741 of 5 stars$197.25-0.2%$255.82+29.7%-4.7%$35.80B$14.98B25.8987,000Analyst ForecastICLRICON Public4.319 of 5 stars$198.11-2.2%$287.00+44.9%-21.0%$16.34B$8.12B22.0941,100Analyst RevisionINCYIncyte4.7858 of 5 stars$71.93-0.7%$76.29+6.1%+19.5%$13.86B$3.70B513.822,524MEDPMedpace4.1215 of 5 stars$337.35+0.2%$380.56+12.8%+17.5%$10.48B$1.89B29.545,900CRLCharles River Laboratories International4.5878 of 5 stars$163.77-1.2%$209.00+27.6%-19.9%$8.37B$4.13B20.5021,800Short Interest ↑Analyst RevisionNews CoverageHigh Trading VolumeMXCTMaxCyte3.1435 of 5 stars$4.94+4.0%$9.50+92.3%-0.4%$522.21M$41.29M-14.5380Gap UpOABIOmniAb2.3179 of 5 stars$3.21+0.9%$9.00+180.4%-46.2%$453.32M$34.16M-5.187Positive News Related Companies and Tools Related Companies bioAffinity Technologies Alternatives Data Knights Acquisition Alternatives iSpecimen Alternatives IQVIA Alternatives ICON Public Alternatives Incyte Alternatives Medpace Alternatives Charles River Laboratories International Alternatives MaxCyte Alternatives OmniAb Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AIKI) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIkido Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIkido Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AIKI Stock Alerts